Introduction
Left ventricular thrombus (LVT) is a well-known complication of acute myocardial infarction (AMI) that can lead to serious thromboembolism. The incidence of LVT in patients with anterior AMI in the era of primary percutaneous coronary intervention (PCI) ranged from 4% to 15%. 1, 2 Previous studies in the pre-thrombolytic and thrombolytic eras demonstrated the efficacy of long-term with vitamin K antagonists (VKA). 3, 4 The guidelines of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC)/American Heart Association (AHA) recommend VKA in patients with LVT after AMI for at least 3-6 months and indefinitely in patients without an increased risk of bleeding. 5, 6 In the primary PCI era, AMI patients receive long-term dual antiplatelet therapy (DAPT).
tain whether long-term anticoagulation in addition to antiplatelet therapy reduces the incidence of systemic embolism (SE) without increasing the number of bleeding events.
The major purposes of this study were to investigate the impact of LVT after AMI on systemic embolic events and the association between anticoagulation status and embolic or bleeding events in AMI patients complicated with LVT.
Methods

Study population
All 2301 consecutive patients who were hospitalized within 1 month of AMI onset at the National Cerebral and Cardiovascular Center between 2001 and 2014 were included. Acute myocardial infarction was defined based on symptoms, biomarker evidence (serum creatine kinase more than twice the upper normal limit), and electrocardiographic changes suggestive of myocardial ischaemia or necrosis (new ST-T changes, new left bundle branch block, or pathological Q wave). 8 In this study, we enrolled patients with AMI complicated by LVT detected using imaging modalities described below. Figure 1 showed this study flow chart. Among consecutive 2301 AMI patients, we excluded 451 patients who had a history of previous myocardial infarction (n = 287), and died during index hospitalization or transferred to another hospital because of comorbidities within 48 h of AMI onset (n = 116). We also excluded 48 AMI patients caused by coronary artery embolism (n = 48), which was a high-risk subgroup of patients with AMI. 9 Finally, we studied 1850 patients.
Assessment of left ventricular thrombus
In this study, LVT was assessed using transthoracic echocardiography, left ventriculography, or cardiac magnetic resonance imaging (CMR). All patients underwent a screening echocardiographic examination on admission and 12-24 h after admission. With transthoracic echocardiography, LVT was defined as an echodense mass adjacent to an abnormally contracting myocardial segment. 10 LVT had to be distinguishable from the underlying myocardium, have a clear thrombus-blood interface, and be visible in more than two views. Echocardiography findings were interpreted independently by two expert cardiologists. Repeat echocardiography was performed before hospital discharge. With gadolinium-enhanced CMR, LVT was identified as a LV mass with low-signal intensity surrounded by high-signal intensity structures such as intracavitary blood or hyperenhanced infarcted myocardium. Left ventricular thrombus was carefully distinguished from microvascular obstruction, which also appears as a dark area in the site of infarction, based on the established criteria. 11 With left ventriculography, LVT was defined as a contrastlucent mass adjacent to an abnormally contracting myocardial segment. Cardiac magnetic resonance imaging or left ventriculography was performed according to the discretion of the attending physicians.
Percutaneous coronary intervention procedure and anti-thrombotic therapy
Primary PCI for patients with ST-elevation myocardial infarction or urgent PCI for patients with non-ST-elevation myocardial infarction was performed, as previously reported. 12 Briefly, patients who underwent primary PCI received heparin consisting of a bolus dose of 5000 units and DAPT with aspirin (loading dose of 162-200 mg followed by 100 mg/day) and clopidogrel (loading dose of 300 mg followed by 75 mg/day), prasugrel (loading dose of 20 mg followed by 3.75 mg/day), or ticlopidine (200 mg/day) in the emergency department, unless contraindicated. Percutaneous coronary intervention was performed with heparin boluses when an activated clotting time of 250-300 s was achieved, followed by continuous infusion of heparin for 24-48 h after hospital admission. The decision to perform urgent coronary angiography and coronary intervention was made by the attending physician.
Patients with LVT were treated with continuous heparin infusion followed by oral anticoagulation. We targeted a therapeutic prothrombin time-international normalized ratio (PT-INR) range of 1.6-2.6 according to the Japanese guidelines for pharmacotherapy of atrial fibrillation (AF). 13 Triple therapy was defined as the combination of DAPT plus an oral anticoagulant.
Study endpoints and data analysis
The primary endpoint was the incidence of SE defined as clinical or radiographic evidence of abrupt vascular insufficiency. 14 The secondary endpoint was incidence of the major bleeding event, defined as moderate, severe, or life-threatening bleeding based on the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) bleeding criteria. 15 Data on all events were obtained through medical records review of each hospital visit, and when necessary, through a questionnaire by letter or phone. Finally, the follow-up rate was 91.2% in all study population. All data were shown as means ± standard deviation for continuous variables and as numbers and percentages of patients for categorical variables. Continuous variables were compared using the t-test and categorical variables were compared with the v 2 test or Fisher's exact test as appropriate. Cumulative incidence was estimated using the Kaplan-Meier method, and differences were assessed with the log-rank test. Time in therapeutic range (TTR) was calculated using the Rosendaal method. 16 We performed two retrospective comparative analyses between the LVT group and the Non-LVT group in all study patients, and between patients with TTR > _50% and those with TTR <50% in LVT patients treated with VKA. Cox proportional hazards regression model was used to identify independent predictors of SE. Variable selection in multivariable models was guided by bootstrap selection with the correction of bias due to small sample size by Harrell et al. 17 A resampling analysis with 1000 iterations was performed to identify the variables that entered into 50% of the logistic regression models to determine the independent predictor of SE (selection criterion: P-values < 0.10) using mfp commands of STATA. 18 The 95% confidence interval (CI) of the covariates in the final predictive models was also obtained from the bootstrapped resampling model. 
Results
Baseline patient characteristics are shown in Table 1 . After a screening test using transthoracic echocardiography, CMR in 257 patients (13.9%) and left ventriculography in 1223 patients (66.2%) were additionally performed, respectively. We found that 92 patients (5.0%) had LVT, which was identified by echocardiography in 52 patients, CMR in 40 patients, and left ventriculography in 17 patients. Twenty two (24%) of 92 LVT patients were diagnosed by several imaging methods and 24 (26%) did not undergo early catheter-based revascularization therapy (see Supplementary material online, Table  S1 ). The most frequent reason for not undergoing early revascularization was late arrival at the hospital, which was >24 h from AMI onset in 20 (83%) patients. In the remaining patients (17%), catheterbased intervention was not performed because of myocardial infarction related to coronary artery bypass grafting and an undetermined culprit lesion. The patients with LVT were younger and had significantly more anterior AMI (P < 0.001), more Killip classification > _2 (P < 0.001), higher peak creatine kinase (P < 0.001), and lower LVEF than those without LVT (P < 0.001) ( Table 1) . There were no significant differences in risk factors of atherosclerosis, comorbidities including AF, carotid artery stenosis and peripheral artery disease, CHADS 2 score, and CHA 2 DS 2 -VASC score between the two groups. All 92 patients with LVT had some antiplatelet therapy and 79 patients received oral anticoagulation therapy. In the remaining 13 patients (14%) without any anticoagulation, 5 patients were diagnosed with LVT after they developed SE, 2 patients were considered at high risk of bleeding (cavernous angioma, n = 1; advanced gastric cancer, n = 1), 1 discontinued anticoagulation to undergo ventricular aneurysm excision, and the remaining 5 patients were determined to be at high risk of bleeding by attending physicians. Median duration of anticoagulation was 34 months [interquartile range (IQR) 7-90 months]. Among all LVT patients, 35 patients (38%) were on triple therapy at discharge. Median duration of triple therapy was 6.6 months (IQR 1.9-12.9 months). Oral anticoagulation was discontinued in 32 (41%) of 79 patients during the follow-up period. The most common reasons for anticoagulation discontinuation were disappearance of LVT (n = 21), bleeding event (n = 7), surgery (n = 3), and unknown (n = 1).
Systemic embolic events occurred in 66 of 1850 first AMI patients (3.6%), in 15 of 92 patients with LVT (16.3%) and in 51 of 1758 patients without LVT (2.9%) during a median follow-up period of 5.4 years (IQR 2.6-9.1 years). The most site of SE was brain (n = 62, 94%). Other sites included superior mesenteric artery (n = 2, 3%), coronary artery (n = 1, 1.5%), and lower limb (n = 1, 1.5%). KaplanMeier analysis shows a significantly higher incidence of SE in the LVT patients (log-rank test, P < 0.001) (Figure 2) . Univariate analysis showed that LVT, age, Killip classification > _2, LVEF on admission, oral anticoagulant, AF, and CHA2DS2-VASC score were the predictors of SE in patients with first AMI. On multivariable analysis, LVT was one of the independent predictors of SE [hazard ratio (HR) 4.00; 95% CI 2.11-7.23; P < 0.001] ( Table 2) . Interaction between LVT and AF, anterior infarction, reperfusion therapy by primary PCI and LVEF for SE were not significant in all study patients (see Supplementary mate rial online, Figure S1 ). By univariate Cox proportional hazard analysis (Figure 3) , in comparison with patients with neither LVT nor AF, HR for SE was significantly higher in patients with LVT and Non-AF (HR 5.2; 95% CI 1.5-6.3, P = 0.001) and in those with AF and Non-LVT (HR 3.2; 95% CI 1.5-6.3, P = 0.005). Highest HR was noted in LVT patients along with AF (HR 15.0; 95% CI 3.6-41, P < 0.001). Supplementary material online, Figure S2 also shows Kaplan-Meier curves (see Supplementary material online, Figure S2 ). We also compared patients enrolled in the first half (2001-07) with those in the second half (2008-14) of our study period (see Supplementary mate rial online, Table S2 ). There were differences in characteristics between two periods such as the use of thienopyridines at the acute phase. However, LVT was the risk of SE in both periods (see
Supplementary material online, Figure S1 ). All three patients on triple therapy with SE were not sufficiently anticoagulated (PT-INR value <1.6) at the time of their systemic embolic event (see Supplementary material online, Table S3 ).
We then compared the LVT patients with TTR of 50% or more (TTR > _50%; n = 34) to those with TTR less than 50% (TTR <50%; n = 50) after excluding five patients who developed SE before LVT diagnosis, two patients with non-valvular AF on a direct oral anticoagulant and one patient without TTR data. The remaining six patients with AF in LVT patients received the VKA, but one discontinued because of the bleeding risk. Table 3 compares the clinical characteristics of the TTR > _50% and TTR <50% groups. There were no significant differences in AF, LVEF, and antiplatelet therapy between the two groups. One embolic event developed in the TTR > _50% group while nine events developed in the TTR <50% group (2.9% vs. 18%, P = 0.036). There was no difference in the incidence of major bleeding events between the two groups during follow-up (9% vs. 8%, P = 0.89). Univariate analysis showed that hypertension, Killip classification > _2, LVEF on admission, TTR, and disappearance of LVT during follow-up were the predictors of SE in the AMI patients with LVT. On multivariable analysis, TTR and LVEF were independently associated with SE (HR 0.76; 95% CI 0.66-0.86; P < 0.001, and HR 0.89; 95% CI 0.82-0.97; P = 0.004 for each per cent increase in Log TTR and LVEF, respectively) ( Table 4) . The results were equivalent to those by the bootstrapped model. Kaplan-Meier analysis shows a significantly higher incidence of SE in the TTR <50% group (P = 0.033) ( Figure 4A ), but there was no significant difference in major bleeding events between the two groups (P = 0.20) (Figure 4B) . Among seven patients who had bleeding events, two developed a major bleeding event while receiving triple therapy (see Supplementary material online, Table S4 ). The remaining five patients developed major bleeding events when anticoagulation was controlled appropriately, with PT-INR in the range of 1.6-2.6 (see Supplementary material online, Table S4 ).
Discussion
The major findings of this study are: (i) the prevalence of LVT was 5.0% in patients with a first AMI; (ii) SE occurred in 3.6% of the first AMI patients, in 16 .3% of the patients with LVT and 2.9% of the patients without LVT during a follow-up of 5.4 years; (iii) On multivariable analysis, LVT was one of the independent predictors of SE;
and (iv) appropriate anticoagulation therapy was associated with a lower incidence of SE without increasing the risk of major bleeding events. Previous studies in the primary PCI era reported that the incidence of LVT in patients with anterior AMI ranged from 4% to 15%. 1, 2 Echocardiography was widely accepted as first-line cardiac imaging for primary screening of LVT. 10, 19 Weinsaft et al. 20 reported that echocardiography, using delayed enhancement CMR as the reference, yielded a sensitivity of 33%, specificity of 91%, and positive and negative predictive values of 29% and 93%, respectively. The relatively low prevalence of LVT in this retrospective study may be related at least in part to the limited application of gadoliniumenhanced CMR.
The clinical problem associated with LVT is the increased risk for SE, especially stroke. In the pre-thrombolytic era, the incidence of embolic complications was 10% to 35% of patients with LVT, whereas in the thrombolytic era, embolic complications occurred in 2-3%. 21, 22 This study demonstrates a high incidence (16.3%) of SE in AMI patients with LVT compared with those without LVT (2.9%) and that LVT is an independent predictor of SE. This study included 26%
of patients who did not receive early revascularization. Early revascularization may lead to improvement in left ventricular dysfunction, and thus a reduced risk for LVT and associated SEs. Furthermore, a higher incidence (16.3%) of SE may be related in part to our followup period of 5.4 years, which was relatively long compared with that in previous studies. 21, 22 In a previous study, severe congestive heart failure, diffuse LV dilatation, systolic dysfunction, previous embolization, AF, and aging were identified as risk factors of SE. 23 In the current guidelines of the ESC and ACC/AHA, anticoagulation therapy was recommended for patients with large anterior wall motion abnormalities. 5, 6 Taken together with our univariate analysis showing that patients with SE have lower LVEF and higher Killip classification on admission, initiation or continuation of anticoagulation therapy should be considered for high-risk patients characterized by low LVEF and congestive heart failure. Furthermore, regarding the duration of anti-thrombotic therapy, current ESC guidelines recommend oral anticoagulation therapy for up to 6 months in AMI patients with LVT. 6 In this study, 47% of SE occurred within 6 months of AMI onset, while 53% of events occurred after 6 months. Our study might suggest that a longer application, i.e. over 6 months, of anticoagulant therapy is required for prevention of SE in AMI patients with LVT. Importantly, only one patient who had TTR > _50% with a PT-INR range of 1.6-2.6 developed SE. This study also demonstrated that inadequate anticoagulation therapy is an important risk factor for SE. In the sub-analysis of the CREDO-Kyoto registry cohort-2 with 12 716 patients undergoing first PCI, of whom 1057 patients (8.3%) had AF, oral anticoagulation therapy at hospital discharge was not associated with a lower incidence of stoke because of the low intensity of anticoagulation therapy. Only 37.7% of patients had TTR > _65% with a PT-INR range of 1.6-2. 6 . 24 However, patients with TTR > _65% had a markedly lower risk of stroke than patients with TTR <65%. Although the target PT-INR (1.6-2.6) was lower in this study, favourable TTR in LVT patients who received DAPT could result in an acceptable risk-benefit ratio.
The main drawback of continuous anticoagulation is the increased risk of haemorrhage. A close relationship between bleeding events and adverse outcomes such as death, stroke, and recurrence of myocardial infarction, has been reported previously. 25 The rates of these adverse outcomes were higher in patients with bleeding events. In particular, in patients taking an antiplatelet agent plus a VKA, continuous anticoagulation was associated with an increased risk of bleeding, CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1 .
a Percent (%) refers as in Table 2 . Figure 4 Kaplan-Meier analysis of the incidence of (A) SE and (B) major bleeding stratified by TTR. (A) The incidence of SE was significantly lower in patients with TTR > _50% (red line) than those with TTR <50% (blue line) (2.9% vs. 18%). (B) There is no significant difference in major bleeding events, defined as moderate, severe, or life-threatening according to GUSTO bleeding criteria, between patients with TTR > _50% and TTR <50% (8% vs. 9%). GUSTO, Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Other abbreviations are shown in Figure 1. . with an estimated absolute rate of 0.5-3.6% per year. 26, 27 Several registries reported that the risk of major bleeding with triple antithrombotic therapy (DAPT plus anticoagulation) was three-fold to four-fold higher than with oral anticoagulation alone or single antiplatelet therapy. [28] [29] [30] Andrade et al. 29 conducted a systematic review and meta-analysis of the risk of bleeding among patients receiving triple therapy after PCI. In their analysis, the pooled estimate of major bleeding was 2.4% at 30 days and 4.6% within 6 months of PCI with a drug-eluting stent. In the recent PIONEER AF-PCI trial with 2124 non-valvular AF patients who had undergone PCI with a mean age of 70 years, the rate of major bleeding determined by Thrombolysis in Myocardial Infarction criteria at 12 months was 3.3% in patients who received a VKA with dose adjustment to achieve a target INR of 2.0-3.0 plus DAPT for 1, 6, or 12 months. 31 In the PIONEER AF-PCI trial, 22% of the patients receiving triple therapy were treated for 1 year, and TTR was 65.0%. In the WOEST trial that enrolled 573 patients with a mean age of 70 years, the rate of moderate and severe GUSTO bleeding events at 1 year was 12.3% in patients on triple therapy. 32 In the WOEST trial, TTR was not calculated, and 66% of patients received triple therapy for 1 year. In this study, mean age was 62 years and the rate of triple therapy was 38% at discharge and decreased to 12% at 1 year of follow-up. The rate of major bleeding events was 1.2% per year in the TTR > _50% group and 1.3% per year in the TTR <50% group. The relatively low bleeding rate in this study might be explained in part by the younger population, lower target PT-INR, or a lower proportion receiving triple therapy compared with previous studies. We should acknowledge several limitations of our study. First, this was a retrospective study from a single centre. Selection bias including therapeutic strategy (e.g. anti-thrombotic therapies) may limit the ability to compare outcomes according to the treatment. Second, we did not perform CMR in all study patients. Because sensitivity and specificity of echocardiography for the detection of LVT are limited, multimodality regimen should be established. Third, incomplete follow-up rate (8.8% lost follow-up) may leave some room for uncertainty in assessment of our results. Finally, sample size of LVT in our study was small. Further large studies are warranted.
Conclusions
Appropriate anticoagulation therapy may decrease the incidence of embolic events without an increase in the incidence of bleeding events in patients with a first AMI complicated by LVT.
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